secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001213900-25-087903
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed
--------------------------------------------------------------------------------

- Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.
- First patient in South Korea dosed; trial enrolling Cohort 2 (8 mg tablet) after SRC cleared Cohort 1 without modification.
- Initial interim clinical data from first two cohorts expected in Q1 2026.
- Phase 1/1b study of PAS-004 (macrocyclic MEK inhibitor) in adult NF1 patients with symptomatic plexiform neurofibromas.
- Trial also includes sites in Australia and U.S.; Part A dose escalation (4 mg to 18 mg) identifying recommended Part B dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/0001213900-25-087903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/ea0257501-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-087903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer